Claudia Meyer has been appointed director of regulatory affairs at Amsterdam Molecular Therapeutics (AMT) of the Netherlands as the company awaits a decision from the European Medicines Agency on its marketing authorisation application for a novel gene therapy. Dr Meyer was previously responsible for European regulatory affairs at Human Genome Sciences Inc. Joining her on the AMT management team will be Gerald Haase who has been appointed senior clinical consultant. Dr Haase was previously a senior medical officer at the UK Medicines and Healthcare products Regulatory Agency.
AMT has also nominated three industry veterans to its Supervisory Board. They are, Joseph Feczko, formerly senior vice president and chief medical officer at Pfizer Inc; Steven Holtzman, executive chairman of Infinity Pharmaceuticals Inc, and François Meyer, former general director for research and development at Aventis Pharma and former director-general of that company’s gene therapy division.
Copyright 2010 Evernow Publishing Ltd